Article

A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly.

Novartis Vaccines and Diagnostics, Via Fiorentina, 1, 53100 Siena, Italy.
Clinical and vaccine Immunology: CVI (Impact Factor: 2.6). 11/2010; 17(11):1817-9. DOI:10.1128/CVI.00461-09
Source: PubMed

ABSTRACT Immunogenicity and safety of a booster dose of an MF59-adjuvanted H5N1 vaccine containing 7.5 μg A/turkey/Turkey/1/2005-like (clade 2.2) H5N1 hemagglutinin, given approximately 18 months after primary vaccination with a heterologous strain, were evaluated. The booster vaccine was well tolerated and induced a robust, cross-reactive immune response.

0 0
 · 
0 Bookmarks
 · 
109 Views
  • [show abstract] [hide abstract]
    ABSTRACT: The spread of highly pathogenic avian H5N1 influenza viruses since 1997 and their virulence for poultry and humans has raised concerns about their potential to cause an influenza pandemic. Vaccines offer the most viable means to combat a pandemic threat. However, it will be a challenge to produce, distribute and implement a new vaccine if a pandemic spreads rapidly. Therefore, efforts are being undertaken to develop pandemic vaccines that use less antigen and induce cross-protective and long-lasting responses, that can be administered as soon as a pandemic is declared or possibly even before, in order to prime the population and allow for a rapid and protective antibody response. In the last few years, several vaccine manufacturers have developed candidate pandemic and pre-pandemic vaccines, based on reverse genetics and have improved the immunogenicity by formulating these vaccines with different adjuvants. Some of the important and consistent observations from clinical studies with H5N1 vaccines are as follows: two doses of inactivated vaccine are generally necessary to elicit the level of immunity required to meet licensure criteria, less antigen can be used if an oil-in-water adjuvant is included, in general antibody titers decline rapidly but can be boosted with additional doses of vaccine and if high titers of antibody are elicited, cross-reactivity against other clades is observed. Prime-boost strategies elicit a more robust immune response. In this review, we discuss data from clinical trials with a variety of H5N1 influenza vaccines. We also describe studies conducted in animal models to explore the possibility of reassortment between pandemic live attenuated vaccine candidates and seasonal influenza viruses, since this is an important consideration for the use of live vaccines in a pandemic setting.
    Virus Research 05/2013; · 2.75 Impact Factor
  • Source
    [show abstract] [hide abstract]
    ABSTRACT: Objective:Having previously demonstrated the feasibility of administering A/H5N1 and seasonal influenza vaccine antigens in an MF59®-adjuvanted tetravalent formulation, we now report on long-term antibody persistence and responses to a booster dose of a combined seasonal-pandemic, tetravalent influenza vaccine in adults.Methods:Primary objective was the evaluation of responses to a booster dose of tetravalent influenza vaccine containing seasonal (A/H1N1, A/H3N2 and B) and avian (A/H5N1, clade 2) influenza strains administered to 265 healthy 18-40 year-old volunteers one year after priming with one or two clade 1 A/H5N1 doses. Secondary objectives were assessment of reactogenicity, safety, and antibody persistence one year after priming with combined seasonal-pandemic, tetravalent vaccine.Results:Responses to seasonal strains met all European licensure criteria; seroprotection rates were 94-100%, 100% and 61-90% for A/H1N1, A/H3N2 and B strains, respectively. Anamnestic responses were observed against homologous and heterologous A/H5N1 strains whether priming with one or two A/H5N1 doses, with a monovalent A/H5N1 vaccine, or tetravalent vaccine.Conclusions:A single dose of MF59-adjuvanted A/H5N1 vaccine given alone or as part of a fixed combination with a seasonal influenza vaccine was sufficient to prime adult subjects, resulting in robust antigen-specific and cross-reactive antibody responses to heterologous booster immunization one year later. These data support the feasibility of incorporating pre-pandemic priming into seasonal influenza vaccination programmes.
    Clinical and vaccine Immunology: CVI 03/2013; · 2.60 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: The elderly population is more susceptible to infections with higher risks of morbidity and mortality. This is caused by the accumulation of immune defects with aging. The best way to protect people against infections is vaccination. Unfortunately, the same immune defects that render the elderly susceptible to infectious diseases also prevent the development of protective immunity following immunization. A good example of this is the influenza vaccine that only protects between 40 and 60% of the vaccinees over 65 years. In the past decade, tremendous efforts have been put toward improving the influenza vaccine for the elderly. We therefore use this example to present various strategies employed to overcome these age-associated immune defects and hence make vaccines more efficacious for the aged.
    Current opinion in immunology 06/2013; · 10.88 Impact Factor

Full-text

View
12 Downloads
Available from
Sep 6, 2012